ECASS II TRIAL

Problem Acute ischaemic stroke
Format -
Treatment Alteplase
Control Placebo
Population 800 patients
Inclusion criteria -
Exclusion criteria -
Follow-up 90 days
Primary endpoint Modified Rankin scale (mRS) at 90 days, dichotomised for favourable (score 0-1) and unfavourable (score 2-6) outcome
Secondary endpoint(s) .
Details .
Brief summary:
PAPER: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
Date 17 Oct 1998
Journal Lancet. 1998 Oct 17;352(9136):1245-51.
Information Alteplase within 6h of onset

No significant benefit from alteplase
-Trend towards efficacy